Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00167310 · ClinicalTrials.gov registry record · Phase 2
Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation
A Phase 2 study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 2
- Development phase
- 57
- Enrollment target
NCT00167310 is a Phase 2 study that has completed, run by University of Pittsburgh. The registered enrollment target is 57 participants.
The verdict
NCT00167310, a Phase 2 study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 57 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the administration of omega-3 polyunsaturated fatty acids, particularly eicosapentaenoic acid (EPA), can be useful both to reduce coronary artery disease (CAD) risk and illness severity in clinically-stable patients with schizophrenia (or schizoaffective disorder), major depression or bipolar disorder (depressed phase) being treated with lipid lowering drugs (e.g., statins).
Interventions
- DRUG Placebo
- DRUG Eicosapentaenoic acid (omega-3 fatty acid)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2005-09 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00167310
The ClinicalTrials.gov registry entry for NCT00167310 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00167310 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00167310 about?
NCT00167310 is a clinical study titled "Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation". The purpose of this study is to determine whether the administration of omega-3 polyunsaturated fatty acids, particularly eicosapentaenoic acid (EPA), can be useful both to reduce coronary artery disease (CAD) risk and illness severity in clinically-stable patients with schizophrenia (or schizoaffec...
What is the current status of trial NCT00167310?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2005-09. Estimated completion is 2015-12.
What interventions are being tested in trial NCT00167310?
The interventions under investigation include: Placebo (DRUG), Eicosapentaenoic acid (omega-3 fatty acid) (DRUG).
Who is sponsoring clinical trial NCT00167310?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.